-Reuters
Expert Ratings for Mirati Therapeutics
Within the last quarter, Mirati Therapeutics (NASDAQ:MRTX) has observed the following analyst ratings:
Uncategorized
Canadian National Railway Executive Says Less Than 1% Of KCS Network Overlaps With CN
-Reuters
Related Posts
Arcadia Biosciences Q2 Sales $3.86M Beat $2.29M Estimate
Arcadia Biosciences (NASDAQ:RKDA) reported quarterly sales of $3.86 million which beat the analyst consensus estimate of $2.29 million by 68.47 percent. This is a 174.59 percent increase over sales of $1.41 million the
Alpine Immune Sciences Earnings Perspective: Return On Capital Employed
Alpine Immune Sciences (NASDAQ:ALPN) brought in sales totaling $4.53 million during Q4 according to data provided by Benzinga Pro. However, earnings decreased 12.4%, resulting in a loss of $15.17 million.
